<DOC>
	<DOCNO>NCT02560220</DOCNO>
	<brief_summary>A phase- I clinical trial determine safety feasibilty intravenous administration mitomycin C-treated donor peripheral blood mononuclear cell patient chronic kidney disease stage KDIGO 4 5 ( i.e . GFR 15-30 mL/min &lt; 15 mL/min ) receive kidney transplant live donor .</brief_summary>
	<brief_title>MIC Cell Therapy Individualized Immunosuppression Living Donor Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Chronic kidney disease stage KDIGO 4 5 First kidney transplant live donor Age â‰¥ 18 year ABO compatible CDCPRA &lt; 20 % No donorspecific antibody Negative CDC ELISA crossmatch Immunosuppression cyclosporin A , ECMPS methylprednisolone Informed consent Adequate contraception ( woman child bear potential ) Psychiatric disorder Heart failure ( NYHA III IV ) Severe liver disease Active hepatitis B C HIV infection Active bacterial , fungal viral disease Malignancy malignancy last 5 year screen Preexisting immunosuppression Vaccination live vaccine last 3 month screen S/p splenectomy Substance abuse Pregnancy lactation Women : Child/pregnancy intend donor Allergy investigational drug part Other diseases prohibit participation study ( opinion investigator ) Participation interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>